Indian pharmaceutical stock company
BRS: Megha Engineering Is Top Donor to the Fourth-Largest Recipient of Electoral Bonds
thewire.in/politics/telangana-brs-megha-kitex-electoral-bonds
Downgrades to keep pharma major Divi's Laboratories' stock under pressure: Divi's Laboratories Share Price: Gross margins improved by 313 basis points on a ...
business-standard.com/markets/stock-market-news/downgrades-to-keep-pharma-major-divi-s-laboratories-stock-under-pressure-124021500990_1.html
Paid articlePaid
India's Divi's Labs Q1 profit slumps on drug pricing pressures: Indian pharmaceutical company Divi's Laboratories (DIVI.NS) reported a 49.2% fall in quarterly ...
reuters.com/business/healthcare-pharmaceuticals/indias-divis-labs-q1-profit-slumps-drug-pricing-pressures-2023-08-14/
Nifty Pharma index hits 2-year low; Cipla, Divis, Laurus Labs at 52-wk lows: Analysts said the pace of US FDA inspections has again pickedup in the last few ...
business-standard.com/article/markets/nifty-pharma-index-hits-2-year-low-cipla-divis-laurus-at-52-week-lows-123031400587_1.html
Divis Lab sinks 13%, hits 29-mth low as Q3 profit falls more than expected: In Q3FY23 Divis Lab reported a 66 per cent yearonyear decline in its consolidated ...
business-standard.com/article/markets/divis-labs-plunges-13-hits-29-month-low-on-weak-q3-results-123020300833_1.html
Half of Nifty 50 stocks yet to reclaim Budget peaks, breadth stays fragile: Selective stocks like Bharat Petroleum Corporation Divis Laboratories Hindalco ...
business-standard.com/article/markets/half-of-nifty-50-stocks-yet-to-reclaim-budget-peaks-breadth-stays-fragile-123021600409_1.html
Paid articlePaid Divis Labs stock tanks 12% on big miss in Q3; near-term trend bearish: Analysts average price target of Rs 3862 however indicates significant upside The nearterm ...
business-standard.com/article/companies/divi-s-labs-stock-tanks-12-on-big-miss-in-q3-near-term-trend-bearish-123020301671_1.html
Paid articlePaid
How much more can Divis Labs fall? | Mint: Is this a good time to buy shares of Divis Laboratories?
equitymaster.com/profit-hunter/detail.asp
Paid articlePaid Debt-free pharma stock makes ₹1 lakh to 16 Cr just after 2 bonus shares: Buy? | Mint
livemint.com/market/stock-market-news/debtfree-pharma-stock-makes-rs-1-lakh-to-16-cr-just-after-2-bonus-shares-buy-11665336091779.html
₹9 to ₹3,578: Multibagger stock turns ₹1 lakh to ₹15.90 Cr in 19 years: Should you buy? | Mint
livemint.com/market/stock-market-news/rs-9-to-rs-3-578-multibagger-stock-turns-rs-1-lakh-to-15-90-cr-in-19-years-11661793615035.html
₹9 to ₹3,721: Debt-free pharma stock turns ₹1 lakh to ₹4.13 Cr in 19 years | Mint
livemint.com/market/stock-market-news/rs-9-to-rs-3-721-debt-free-stock-turns-rs-1-lakh-to-rs-4-13-cr-in-19-years-11660560108645.html
Divi's Labs Q1 results: Net profit rises 26% to ₹702 crore | Mint: Divis Laboratories revenue from operations rose about 15% to ₹2,254 crore from ₹1,960 ...
livemint.com/companies/company-results/divis-labs-q1-results-net-profit-rises-26-to-rs-702-crore-stock-plunges-11660287963140.html
New to NewsWall?
Sign up now to get your own personalized news!
Trending topics